NuScale is in a sustained, severe downtrend, with the 1-year price change at -78.31% and the current price of $8.27 sitting at just 2.1% above its 52-week low of $7.21 and 85.6% below its 52-week high of $57.42 — effectively at the very bottom of its 52-week range (approximately 2% of range). This positioning reflects persistent distribution rather than a basing pattern, and with a maximum drawdown of -85.79%, the stock has destroyed the majority of its prior-cycle value; traders should treat this as a falling-knife setup where "cheap" is a function of collapsing expectations rather than a valuation floor. The relative strength figures reinforce the damage: -93.32% versus SPY over 1 year and -60.99% year-to-date, meaning the stock has massively underperformed a market that itself rose 15.01% over the past year.\n\nShort-term momentum is negative but less catastrophic than the annual trend, with the 1-month change at -10.98% and the 3-month change at -29.56%, both deteriorating versus the 6-month change of -27.71%. The most recent session saw an -8.52% single-day drop from $9.04 to $8.27, erasing a brief early-September spike to $11.18 on September 8 — a failed rally that reversed violently within three sessions, which is characteristic of bear-market rallies rather than trend reversals. Momentum is therefore decelerating rather than stabilizing: the 1-month relative strength of -10.02% versus SPY confirms the stock is losing ground even as the broader market is roughly flat (-0.96% for SPY over 1 month), and the elevated volume of 64.1 million shares on a sub-$10 stock suggests heavy speculative turnover and capitulation-style selling rather than accumulation.\n\nKey technical levels are unusually well-defined: support sits at the 52-week low of $7.21, just $1.06 (12.8%) below the current $8.27 price, while resistance is anchored at the 52-week high of $57.42, a level so distant it is functionally irrelevant to near-term trading. A breakdown below $7.21 would signal a fresh leg lower and likely trigger momentum-driven selling, whereas a sustained reclaim of the September 8 high of $11.18 would be the first evidence of a genuine trend change. Volatility risk is extreme: the beta of 2.309 means the stock is roughly 131% more volatile than the market, so a 1% SPY move implies a ~2.3% SMR move — position sizing must be dramatically reduced relative to a market-weight holding, and the short ratio of 1.91 days indicates bears are not yet aggressively pressed but have ample room to add.

NuScale's revenue trajectory is deteriorating sharply and is effectively non-existent at commercial scale: Q1 2026 revenue was just $565,000, a -95.78% year-over-year decline from $13.375 million in Q1 2025, and down sequentially from $1.808 million in Q4 2025 and $8.242 million in Q3 2025. The multi-quarter trend shows revenue collapsing from $34.224 million in Q4 2024 to sub-$1 million levels, reflecting the completion of early engineering and licensing service work without replacement commercial contracts; the only disclosed segment is "Other" at $32,000, underscoring the absence of a diversified revenue base. For the investment case, this means the company is entirely a call option on future contract awards — there is no current earnings stream to anchor valuation, and the analyst consensus revenue estimate of $1.487 billion (range $690 million to $2.994 billion) implies the market is pricing in a step-function inflection that has not yet appeared in reported results.\n\nProfitability remains deeply negative and is worsening on a margin basis: Q1 2026 net income was -$44.015 million on $565,000 of revenue, producing a net margin of -77.90% and an operating margin of -101.81%, with gross profit of -$244,000 (gross margin of -43.19%) — meaning the company loses money on the direct cost of the little revenue it books. The trailing net margin of -11.30% and gross margin of 36.31% in the key metrics data reflect a longer averaging period that masks the recent deterioration, while the quarterly income statement shows operating expenses of $57.28 million (including $12.805 million of R&D and $24.839 million of G&A) against negligible revenue. Compared to typical capital-goods and electrical equipment peers, which generally operate at 10-20% net margins, NuScale's negative gross margin is an outlier that reflects a pre-commercial cost structure; the loss trajectory is not narrowing — Q1 2026's -$44.015 million net loss compares unfavorably to Q1 2025's -$14.005 million, though the Q3 2025 loss of -$273.319 million was inflated by a $519.222 million G&A charge tied to non-cash items.\n\nThe balance sheet is the company's one genuine strength but is being consumed rapidly: debt-to-equity is 0 and the current ratio is 4.30 (with a quick ratio of 29.36 in the Q1 2026 historical ratios data), and cash stood at $346.229 million at quarter-end versus $841.517 million at the start of Q1 2026 — a $495.288 million net cash decline in a single quarter. Free cash flow is deeply negative at -$316.2 million for Q1 2026 and -$753.465 million on a trailing twelve-month basis, with operating cash flow of -$314.678 million, meaning the company is burning cash at a rate that would exhaust its remaining $346 million in roughly one to two quarters absent new financing. The company has been funding itself through equity issuance — $737.882 million of common stock issued in Q4 2025 and $37.792 million in Q1 2026 — which is highly dilutive (shares outstanding rose from 127.7 million in Q1 2025 to 163.7 million in Q1 2026, a 28% increase) and explains the ROE of -30.44% and ROA of -10.60%; with no debt and no dividend, the FCF yield is deeply negative and the equity story depends entirely on capital markets remaining open to pre-revenue nuclear developers.